{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for phenyl root_names_stdName in Standardized Name (approximate match)
Status:
US Previously Marketed
Source:
CO-PYRONIL PYRROBUTAMINE NAPHTHALENE DISULFONATE by DISTA PRODUCTS
(1961)
Source URL:
First approved in 1952
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
PYRROBUTAMINE is a potent H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate the inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria.
Status:
US Previously Marketed
Source:
CO-PYRONIL PYRROBUTAMINE NAPHTHALENE DISULFONATE by DISTA PRODUCTS
(1961)
Source URL:
First approved in 1952
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
PYRROBUTAMINE is a potent H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate the inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria.
Status:
US Previously Marketed
First approved in 1952
Class (Stereo):
CHEMICAL (ACHIRAL)
Acetosulfone (promacetin®) (sodium 4,4′-diaminodiphenylsulfone-2-acetylsulfonamide) is much less toxic sulfone than sulfoxone sodium (diasone®). Acetosulfone is an antibacterial agent. It has been used in the treatment of leprosy, has been under study in the Department of Dermatology at the University of Cincinnati College of Medicine since 1949. Acetosulfone was also used for the treatment of sarcoidosis. It was tested in the treatment of the Duhring's disease.
Status:
US Previously Marketed
Source:
TROCINATE/PHENOBARB THIPHENAMIL HYDROCHLORIDE by POYTHRESS
(1961)
Source URL:
First approved in 1950
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Thiphenamil, an antispasmodic drug with a local anesthetic activity, inhibits contraction. The clinical trials have shown that thiphenamil could suppress upper urinary tract contractility, and was suggested to use the drug for renal colic and stone management. In addition, this drug was studied for the treatment of detrusor incontinence in patients with detrusor instability. The results showed, that the drug caused a significant decrease in problems due to loss of urine when the patient was taking the drug compared to the placebo.
Status:
US Previously Marketed
First approved in 1949
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
ALPHAPRODINE is an opioid analgesic. It was used in obstetrics, as pre-operative medication, and for minor surgical procedures. In addition, this drug was used in the dentistry setting to help effectively manage pain associated with dental procedures.
Status:
First approved in 1949
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Caramiphen is a muscarinic M1 acetylcholine receptor antagonist, which was used for the treatment of Parkinson Disease and cough, but then there using were discontinued. Caramiphen is also used in local anesthesia, and effect could be achieved through the suppression of voltage-gated Na⁺ currents.
Status:
First approved in 1949
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
THIANTOIN (also known as phethenylate) is an anticonvulsant drug.
Status:
US Previously Marketed
Source:
VASOCON-A by NOVARTIS
(1990)
Source URL:
First approved in 1948
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Antazoline is an antagonist of histamine H1 receptors. It selectively bind to but does not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Antazoline in combination with naphazoline (VASOCON-A®) is indicated to relieve the symptoms of allergic conjunctivitis.
Status:
US Previously Marketed
Source:
VASOCON-A by NOVARTIS
(1990)
Source URL:
First approved in 1948
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Antazoline is an antagonist of histamine H1 receptors. It selectively bind to but does not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Antazoline in combination with naphazoline (VASOCON-A®) is indicated to relieve the symptoms of allergic conjunctivitis.
Status:
US Previously Marketed
Source:
VASOCON-A by NOVARTIS
(1990)
Source URL:
First approved in 1948
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Antazoline is an antagonist of histamine H1 receptors. It selectively bind to but does not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Antazoline in combination with naphazoline (VASOCON-A®) is indicated to relieve the symptoms of allergic conjunctivitis.